Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
03/07/2024 | 22:00 | GlobeNewswire Inc. | Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | NASDAQ:ARQT | Arcutis Biotherapeutics Inc |
18/06/2024 | 22:52 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:ARQT | Arcutis Biotherapeutics Inc |
18/06/2024 | 22:47 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:ARQT | Arcutis Biotherapeutics Inc |
10/06/2024 | 20:30 | GlobeNewswire Inc. | Arcutis Announces New Long-Term Data of Roflumilast Cream 0.15% for the Treatment of Mild to Moderate Atopic Dermatitis (AD) in Adults and Children Down to Age Six Presented at Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference | NASDAQ:ARQT | Arcutis Biotherapeutics Inc |
05/06/2024 | 14:00 | GlobeNewswire Inc. | Arcutis Announces Multiple Abstracts, Including Oral Presentation, Accepted at the Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference | NASDAQ:ARQT | Arcutis Biotherapeutics Inc |
04/06/2024 | 20:03 | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NASDAQ:ARQT | Arcutis Biotherapeutics Inc |
03/06/2024 | 14:00 | GlobeNewswire Inc. | Arcutis to Present at the Goldman Sachs 45th Annual Global Healthcare Conference | NASDAQ:ARQT | Arcutis Biotherapeutics Inc |
28/05/2024 | 13:00 | PR Newswire (Canada) | Arcutis Canada annonce l'acceptation aux fins d'examen par Santé Canada de la présentation de la crème de roflumilast à 0,15 % pour le traitement de la dermatite atopique chez les adultes et les enfants âgés de 6 ans et plus | NASDAQ:ARQT | Arcutis Biotherapeutics Inc |
14/05/2024 | 22:00 | GlobeNewswire Inc. | Arcutis Announces First Quarter 2024 Financial Results and Provides Business Update | NASDAQ:ARQT | Arcutis Biotherapeutics Inc |
14/05/2024 | 13:18 | IH Market News | US Futures Remain Steady Amid Wall Street Caution Ahead of April PPI Report | NASDAQ:ARQT | Arcutis Biotherapeutics Inc |
13/05/2024 | 14:00 | GlobeNewswire Inc. | Expert Panel Review Further Validates Use of ZORYVE® (roflumilast) Topical Foam, 0.3% for Treatment of Seborrheic Dermatitis Across Diverse Hair Types Published in Journal of Clinical and Aesthetic Dermatology | NASDAQ:ARQT | Arcutis Biotherapeutics Inc |
29/04/2024 | 22:00 | GlobeNewswire Inc. | Arcutis to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024 | NASDAQ:ARQT | Arcutis Biotherapeutics Inc |
10/04/2024 | 14:00 | GlobeNewswire Inc. | Arcutis Appoints David Topper as Chief Financial Officer | NASDAQ:ARQT | Arcutis Biotherapeutics Inc |
01/04/2024 | 13:00 | GlobeNewswire Inc. | Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream | NASDAQ:ARQT | Arcutis Biotherapeutics Inc |
28/03/2024 | 13:00 | GlobeNewswire Inc. | Arcutis to Present at the 23rd Annual Needham Virtual Healthcare Conference | NASDAQ:ARQT | Arcutis Biotherapeutics Inc |
11/03/2024 | 13:00 | GlobeNewswire Inc. | Arcutis Promotes Todd Tucker to Chief Human Resources Officer | NASDAQ:ARQT | Arcutis Biotherapeutics Inc |
10/03/2024 | 21:00 | GlobeNewswire Inc. | Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual Meeting | NASDAQ:ARQT | Arcutis Biotherapeutics Inc |
09/03/2024 | 22:00 | GlobeNewswire Inc. | New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction | NASDAQ:ARQT | Arcutis Biotherapeutics Inc |
04/03/2024 | 22:00 | GlobeNewswire Inc. | Arcutis Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares | NASDAQ:ARQT | Arcutis Biotherapeutics Inc |
04/03/2024 | 14:00 | GlobeNewswire Inc. | Arcutis Announces Acceptance of Late Breaking Abstract in Atopic Dermatitis Among Five New Topical Roflumilast Data Being Presented at the American Academy of Dermatology Annual Meeting | NASDAQ:ARQT | Arcutis Biotherapeutics Inc |
01/03/2024 | 22:06 | Edgar (US Regulatory) | Form 424B5 - Prospectus [Rule 424(b)(5)] | NASDAQ:ARQT | Arcutis Biotherapeutics Inc |
29/02/2024 | 23:00 | GlobeNewswire Inc. | Arcutis to Present at the TD Cowen 44th Annual Health Care Conference | NASDAQ:ARQT | Arcutis Biotherapeutics Inc |
29/02/2024 | 05:30 | GlobeNewswire Inc. | Arcutis Announces Pricing of $150 Million Public Offering | NASDAQ:ARQT | Arcutis Biotherapeutics Inc |
28/02/2024 | 22:10 | GlobeNewswire Inc. | Arcutis Announces Proposed Public Offering | NASDAQ:ARQT | Arcutis Biotherapeutics Inc |
28/02/2024 | 22:00 | GlobeNewswire Inc. | Arcutis and Sato Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Japan | NASDAQ:ARQT | Arcutis Biotherapeutics Inc |
27/02/2024 | 22:34 | Edgar (US Regulatory) | Form S-8 - Securities to be offered to employees in employee benefit plans | NASDAQ:ARQT | Arcutis Biotherapeutics Inc |
27/02/2024 | 13:48 | Edgar (US Regulatory) | Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] | NASDAQ:ARQT | Arcutis Biotherapeutics Inc |
27/02/2024 | 11:50 | GlobeNewswire Inc. | Arcutis Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update | NASDAQ:ARQT | Arcutis Biotherapeutics Inc |
16/02/2024 | 14:00 | GlobeNewswire Inc. | Arcutis to Report Fourth Quarter and Full Year 2023 Financial Results | NASDAQ:ARQT | Arcutis Biotherapeutics Inc |
15/02/2024 | 22:19 | Edgar (US Regulatory) | Form SC TO-I/A - Tender offer statement by Issuer: [Amend] | NASDAQ:ARQT | Arcutis Biotherapeutics Inc |